Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Andrea Tubaro; Jose E. Batista; Victor W. Nitti; Sender Herschorn; Christopher R. Chapple; Mary Beth Blauwet; Emad Siddiqui; Moses Huang; Matthias Oelke

doi:10.1177/1756287217702797

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies

Andrea Tubaro^*, Jose E. Batista, Victor W. Nitti, Sender Herschorn, Christopher R. Chapple, Mary Beth Blauwet, Emad Siddiqui, Moses Huang, Matthias Oelke

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	137-154
Number of pages	18
Journal	Therapeutic Advances in Urology
Volume	9
Issue number	6
DOIs	https://doi.org/10.1177/1756287217702797
Publication status	Published - Jun 2017

Keywords

benign prostatic enlargement
benign prostatic hyperplasia
LUTS
male patients
mirabegron
overactive bladder
URINARY-TRACT SYMPTOMS
BENIGN PROSTATIC HYPERPLASIA
QUALITY-OF-LIFE
DOUBLE-BLIND
BETA(3)-ADRENOCEPTOR AGONIST
OUTLET OBSTRUCTION
3-ADRENOCEPTOR AGONIST
MEN
POPULATION
IMPACT

Access to Document

10.1177/1756287217702797

Cite this

Tubaro, Andrea ; Batista, Jose E. ; Nitti, Victor W. ; Herschorn, Sender ; Chapple, Christopher R. ; Blauwet, Mary Beth ; Siddiqui, Emad ; Huang, Moses ; Oelke, Matthias. / Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder : a critical analysis of five phase III studies. In: Therapeutic Advances in Urology. 2017 ; Vol. 9, No. 6. pp. 137-154.

@article{6724c086ae27447e984e40448b031d40,

title = "Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies",

keywords = "benign prostatic enlargement, benign prostatic hyperplasia, LUTS, male patients, mirabegron, overactive bladder, URINARY-TRACT SYMPTOMS, BENIGN PROSTATIC HYPERPLASIA, QUALITY-OF-LIFE, DOUBLE-BLIND, BETA(3)-ADRENOCEPTOR AGONIST, OUTLET OBSTRUCTION, 3-ADRENOCEPTOR AGONIST, MEN, POPULATION, IMPACT",

author = "Andrea Tubaro and Batista, {Jose E.} and Nitti, {Victor W.} and Sender Herschorn and Chapple, {Christopher R.} and Blauwet, {Mary Beth} and Emad Siddiqui and Moses Huang and Matthias Oelke",

year = "2017",

month = jun,

doi = "10.1177/1756287217702797",

language = "English",

volume = "9",

pages = "137--154",

journal = "Therapeutic Advances in Urology",

issn = "1756-2872",

publisher = "SAGE Publications Ltd",

number = "6",

}

Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder : a critical analysis of five phase III studies. / Tubaro, Andrea; Batista, Jose E.; Nitti, Victor W.; Herschorn, Sender; Chapple, Christopher R.; Blauwet, Mary Beth; Siddiqui, Emad; Huang, Moses; Oelke, Matthias.

In: Therapeutic Advances in Urology, Vol. 9, No. 6, 06.2017, p. 137-154.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder

T2 - a critical analysis of five phase III studies

AU - Tubaro, Andrea

AU - Batista, Jose E.

AU - Nitti, Victor W.

AU - Herschorn, Sender

AU - Chapple, Christopher R.

AU - Blauwet, Mary Beth

AU - Siddiqui, Emad

AU - Huang, Moses

AU - Oelke, Matthias

PY - 2017/6

Y1 - 2017/6

KW - benign prostatic enlargement

KW - benign prostatic hyperplasia

KW - LUTS

KW - male patients

KW - mirabegron

KW - overactive bladder

KW - URINARY-TRACT SYMPTOMS

KW - BENIGN PROSTATIC HYPERPLASIA

KW - QUALITY-OF-LIFE

KW - DOUBLE-BLIND

KW - BETA(3)-ADRENOCEPTOR AGONIST

KW - OUTLET OBSTRUCTION

KW - 3-ADRENOCEPTOR AGONIST

KW - MEN

KW - POPULATION

KW - IMPACT

U2 - 10.1177/1756287217702797

DO - 10.1177/1756287217702797

M3 - Article

VL - 9

SP - 137

EP - 154

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

SN - 1756-2872

IS - 6

ER -